Limited Period Offer:Be a PRO for 1 month @Rs49/-Multiple payment options available. Know More
you are here: HomeNewsIndia

COVID-19 update: Gilead announces steps to boost remdesivir production in India, donates 4.5 lakh vials

Remdesivir is approved in India for restricted emergency use for the treatment of COVID-19 in adults and children hospitalised with severe disease.

April 27, 2021 / 10:06 AM IST
Gilead will also donate at least 450,000 vials of Veklury (remdesivir) to help address the immediate needs of Indian patients, the company said.

Gilead will also donate at least 450,000 vials of Veklury (remdesivir) to help address the immediate needs of Indian patients, the company said.

American biopharmaceutical company Gilead has announced steps to expand the availability of remdesivir, a key therapeutic medicine used in the treatment of COVID-19 patients, in India.

Remdesivir is approved in India for restricted emergency use for the treatment of suspected or laboratory-confirmed COVID-19 in adults and children hospitalised with severe disease.

Track this LIVE blog for latest update on coronavirus pandemic

"The recent surge of COVID-19 cases in India is having a devastating impact on communities and has created unprecedented pressure on health systems, Johanna Mercier, chief commercial officer of Gilead Sciences said on Monday.

The company announced that it was providing its voluntary licensing partners technical assistance, support for the addition of new local manufacturing facilities and donation of active pharmaceutical ingredient (API) to rapidly scale up the production of remdesivir.

Close

COVID-19 Vaccine

Frequently Asked Questions

View more
How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.

View more
Show

Read: These countries have offered to help India amid surge in cases

In addition to providing support to its licences to expand local manufacturing capacity, Gilead will also donate at least 450,000 vials of Veklury (remdesivir) to help address the immediate needs of Indian patients, the company said.

We are committed to doing our part to help tackle this crisis. Our immediate focus is to help address the needs of patients in India who may benefit from remdesivir as quickly as we can by working together with the government, health authorities and our voluntary licensees, Mercier said.

All seven of Gilead's licences based in India have significantly accelerated production of remdesivir by scaling up their batch sizes, adding new manufacturing facilities and/or onboarding local contract manufacturers across the country, it said.

Also read: What to do if someone in your family tests positive for COVID-19

While these efforts are expected to increase the availability of remdesivir in the coming weeks, Gilead said it will also donate at least 450,000 vials of Veklury to the government of India to help ease the immediate need for treatment.

Gilead's voluntary licensing programme for remdesivir, established in May 2020, has already enabled access to the drug for more than 2.3 million people in more than 60 low and middle-income countries.

The programme, which builds on Gilead's pioneering voluntary licensing model for its HIV and viral hepatitis medicines, provides long-term licences to nine manufacturers, seven of which are based in India, to enable access to remdesivir in 127 countries.

Click here for Moneycontrol's full coverage of the COVID-19 outbreak
PTI
first published: Apr 27, 2021 10:06 am

stay updated

Get Daily News on your Browser
Sections